Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition.

@article{Wiernik2013TargetingNK,
  title={Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition.},
  author={Andres Wiernik and Bree Foley and Bin Zhang and Michael R. Verneris and Erica D Warlick and Michelle K. Gleason and Julie A. Ross and Xianghua Luo and Daniel J. Weisdorf and Bruce Walcheck and Daniel A. Vallera and Jeffrey S Miller},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2013},
  volume={19 14},
  pages={3844-55}
}
PURPOSE The graft versus leukemia effect by natural killer (NK) cells prevents relapse following hematopoietic stem cell transplantation. We determined whether a novel bispecific killer cell engager (BiKE) signaling through CD16 and targeting CD33 could activate NK cells at high potency against acute myelogenous leukemia (AML) targets. EXPERIMENTAL DESIGN We investigated the ability of our fully humanized CD16 × CD33 (CD16 × 33) BiKE to trigger in vitro NK cell activation against HL60 (CD33… CONTINUE READING
52 Citations
48 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 52 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 48 references

Similar Papers

Loading similar papers…